WebA Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302) Latest version (submitted September 15, 2024) on ClinicalTrials.gov. A study version is represented by a row in the table. Select two study versions to compare. One each from columns A and B. WebMay 6, 2024 · Pemigatinib is currently being studied in FIGHT-302 ... Phase 3 study of BGJ398 (oral infigratinib) in first line chol-angiocarcinoma with FGFR2 gene fusions/translocations. Updated January 27, 2024.
Did you know?
WebSep 4, 2024 · A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin …
WebJul 17, 2024 · FIGHT-302 is a global, Phase III, open-label, randomized, active-controlled, multicenter study to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in ... WebFeb 2, 2024 · Pemigatinib, a selective FGFR1–3 inhibitor, has demonstrated antitumor activity in FIGHT-202, a phase II study in patients with cholangiocarcinoma harboring FGFR2 fusions/rearrangements, and has gained regulatory approval in the United States. Eligibility for FIGHT-202 was assessed using genomic profiling; here, these data were …
WebJun 4, 2024 · Currently, the program is comprised of the recently initiated FIGHT-302 study, and three Phase 2 studies: FIGHT-201 in patients with metastatic or surgically … WebTPS592 Background: For advanced CCA, standard of care 1L systemic treatment is GEM + CIS. Genetic alterations in intrahepatic CCA provide potential therapeutic targets. …
WebFeb 1, 2024 · The FIGHT-302 trial (NCT03656536) is a global, multicenter, openlabel, randomized phase III study that will compare the treatment of CCA with FGFR2 rearrangements with first-line pemigatinib ...
WebNov 3, 2024 · A phase III FIGHT-302 study (NCT03656536) is ongoing to compare the efficacy of pemigatinib versus chemotherapy as first-line treatment for unresectable or metastatic cholangiocarcinoma with FGFR2 alterations. Infigratinib (BGJ398) is a dianimopyrimidine derivative that selectively targets FGFR1–3. ... scanman middlesbroughWebFIGHT-302, a randomized, open-label, phase 3 study, will evaluate efficacy and safety of first-line pemigatinib vs gemcitabine + cisplatin in unresectable/metastatic … scan mar asWebJul 17, 2024 · We describe the study design of FIGHT-302, an open-label, randomized, active-controlled, multicenter, global, Phase III study comparing the efficacy and safety … scan many pages into one fileWeb2 days ago · In the study, about 500 gay men, bisexual men and transgender women in Seattle and San Francisco with previous STD infections took one doxycycline pill within 72 hours of unprotected sex. Those who took the pills were about 90% less likely to get chlamydia, about 80% less likely to get syphilis, and more than 50% less likely to get … scanmar 33 bluewaterWebThis timeline of the fourth phase of the Russian invasion of Ukraine covers the period from 12 November 2024, after both Ukrainian counteroffensives ended, to the present day. Starting in October, Russia began a campaign of massive strikes against Ukrainian infrastructure, which continued into the next phase.Russia achieved some advances, … rubykicks couponsWebFeb 20, 2024 · FIGHT-205, a randomized, open-label, phase 2 study, will assess efficacy and safety of PEMI + PEMBRO vs PEMI alone vs SOC (carboplatin [CARB] + gemcitabine [GEM] or PEMBRO alone) in CIS-ineligible ... ruby kisses cosmeticsWebJul 17, 2024 · We describe the study design of FIGHT-302, an open-label, randomized, active-controlled, multicenter, global, Phase III study comparing the efficacy and safety of first-line pemigatinib versus gemcitabine plus cisplatin in patients with advanced CCA with FGFR2 rearrangements (NCT03656536). The primary end point is progression-free … ruby kholifah